Par acquires three generics from Teva

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has acquired the rights to three generic drugs from another company.

Par said it has acquired from Teva Pharmaceutical Industries the abbreviated new drug applications for fentanyl citrate lozenges and cyclobenzaprine ER capsules (generic versions of Actiq and Amrix, respectively), as well as the U.S. rights to market modafinil tablets, the generic version of Provigil. The acquired rights were in connection to Teva's acquisition of drug maker Cephalon, which was completed Friday.

Par currently is shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva. Cyclobenzaprine ER capsules and modafinil tablets were not previously marketed by Teva and are not yet available, Par said.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.